Biomarker-Defined Subsets of Common Diseases: Policy and Economic Implications of Orphan Drug Act Coverage
Open Access
- 3 January 2017
- journal article
- Published by Public Library of Science (PLoS) in PLOS Medicine
- Vol. 14 (1) , e1002190
Abstract
Aaron Kesselheim and colleagues examine orphan-designated drugs approved between 2009 and 2015 in the United States.Keywords
This publication has 17 references indexed in Scilit:
- Lenalidomide for Second-line Treatment of Advanced Hepatocellular CancerAmerican Journal of Clinical Oncology, 2015
- Off-label use of medicine: Perspective of physicians, patients, pharmaceutical companies and regulatory authoritiesJournal of Pharmacology and Pharmacotherapeutics, 2014
- Regulators adopt more orphan drugsNature, 2014
- Prevalence of Off-Label Use and Spending in 2010 Among Patent-Protected Chemotherapies in a Population-Based Cohort of Medical OncologistsJournal of Clinical Oncology, 2013
- The Prevalence and Cost of Unapproved Uses of Top-Selling Orphan DrugsPLOS ONE, 2012
- Characteristics of Clinical Trials to Support Approval of Orphan vs Nonorphan Drugs for CancerJAMA, 2011
- The US Orphan Drug Act: Rare disease research stimulator or commercial opportunity?Health Policy, 2010
- Pivotal studies of orphan drugs approved for neurological diseasesAnnals of Neurology, 2009
- Off-Label Promotion, On-Target SalesPLOS Medicine, 2008
- The off-label use of drugs in oncology: a position paper by the European Society for Medical Oncology (ESMO)Annals of Oncology, 2007